Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4SC AGFRA:VSC Equity-to-Asset is 0.01 as of Dec. 2025, which is 99% below its 10-year median of 0.83. The stock has 7 warning signs investors should review.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 4SC AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €0.05 Mil. 4SC AG's Total Assets for the quarter that ended in Dec. 2025 was €7.82 Mil.
Therefore, 4SC AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.01.
The historical rank and industry rank for 4SC AG's Equity-to-Asset or its related term are showing as below:
FRA:VSC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01 Med: 0.83 Max: 0.93
Current: 0.01
During the past 13 years, the highest Equity to Asset Ratio of 4SC AG was 0.93. The lowest was 0.01. And the median was 0.83.
FRA:VSC's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.68
vs FRA:VSC: 0.01
4SC AG (FRA:VSC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
4SC AG Equity-to-Asset Related Terms
4SC AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for 4SC AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VSC vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, 4SC AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4SC AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4SC AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where 4SC AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
4SC AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4SC AG (FRA:VSC) has a Equity-to-Asset of 0.01 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4SC AG and its competitors. This is 99% below median its historical median of 0.83. Over the past decade, 4SC AG's Equity-to-Asset has ranged from 0.01 to 0.93.
Is 4SC AG's Equity-to-Asset too high?
4SC AG's current Equity-to-Asset of 0.01 is 99% below median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. 4SC AG's value of 0.01 is 98.5% below this industry median.
How does 4SC AG's Equity-to-Asset compare to VRTX and REGN?
4SC AG's Equity-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. 4SC AG's value of 0.01 is 98.5% below this benchmark. Historically, 4SC AG's own Equity-to-Asset has ranged from 0.01 to 0.93 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.68, 4SC AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4SC AG's current Equity-to-Asset of 0.01 is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4SC AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4SC AG's current Equity-to-Asset is 0.01, which is 99% below median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current Equity-to-Asset of 0.01. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current Equity-to-Asset is 0.01, which is 99% below median its 10-year median of 0.83 and 98.5% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current Equity-to-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VSC has been successfully added to your 
